SCHEMBL5355445

SCHEMBL5355445

CC(C)C(=O)c1cc(S(=O)(=O)N(C)CCc2ccc(F)cc2)c(NC(=O)OC(C)(C)C)s1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.38
KCNQ4 P56696 3/20 0.37
KCNQ5 Q9NR82 3/20 0.37
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
F10 P00742 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
RORC P51449 2/20 0.33
RXFP1 Q9HBX9 1/20 0.33
MEN1 O00255 2/20 0.33
POLB P06746 2/20 0.33
KMT2A Q03164 2/20 0.33
CA2 P00918 1/20 0.33
KCNJ6 P48051 1/20 0.32
KCNJ5 P48544 1/20 0.32
KCNJ3 P48549 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5354265 0.90 KCNQ4 (0.38) TP53KCNQ4KCNQ5CTSSCTSK
SCHEMBL5350786 0.85 KMT2A (0.39) TP53KCNQ4KCNQ5CTSSCTSK
SCHEMBL5354604 0.83 KCNQ4 (0.34) TP53KCNQ4KCNQ5RORCRXFP1
SCHEMBL5355451 0.83 NR1H2 (0.38) KCNQ4KCNQ5CTSSCTSKRORC
SCHEMBL5349250 0.81 KCNQ4 (0.39) TP53KCNQ4KCNQ5CTSSCTSK
SCHEMBL5348107 0.81 TP53 (0.31) TP53KCNQ4KCNQ5RORC
SCHEMBL5350418 0.76 AOC3 (0.35) TP53KCNQ4KCNQ5RORC
SCHEMBL5348137 0.73 AOC3 (0.33) KCNQ4KCNQ5RORC
SCHEMBL5366844 0.73 AOC3 (0.33) KCNQ4KCNQ5RORC
SCHEMBL5348143 0.73 AOC3 (0.33) KCNQ4KCNQ5RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 TP53 1520/4885KCNQ4 2304/4885KCNQ5 2318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.